Investigators evaluated patient-reported outcomes and tolerability of capivasertib plus abiterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...
The drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway, researchers have discovered. A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt ...
PTEN, a tumor suppressor gene mutated in about 20% of prostate cancers, relies on another gene, ARID4B, to function. PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate ...
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results